Aura Biosciences Files 8-K on Shareholder Vote Matters

Ticker: AURA · Form: 8-K · Filed: 2025-06-18T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: AURA

TL;DR

Aura Bio (AURA) filed an 8-K for shareholder vote matters on 6/17.

AI Summary

Aura Biosciences, Inc. filed an 8-K on June 18, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 17, 2025. The filing details corporate actions and shareholder decisions for the company, which is incorporated in Delaware and headquartered in Boston, Massachusetts.

Why It Matters

This filing indicates that Aura Biosciences held a shareholder meeting or took actions requiring a vote, which is a key governance event for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine corporate filing regarding a shareholder vote, not indicating any immediate financial distress or significant operational change.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Aura Biosciences' security holders?

The filing states that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the provided excerpt of the 8-K.

When did the events requiring a vote by security holders take place?

The earliest event reported, which pertains to the submission of matters to a vote of security holders, occurred on June 17, 2025.

What is the principal executive office address for Aura Biosciences, Inc.?

The principal executive offices of Aura Biosciences, Inc. are located at 80 Guest Street, Boston, Massachusetts, 02135.

What is the Commission File Number for Aura Biosciences, Inc.?

The Commission File Number for Aura Biosciences, Inc. is 001-40971.

Under which section of the Securities Exchange Act of 1934 is this Form 8-K being filed?

This Form 8-K is being filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0000950170-25-087885.txt : 20250618 0000950170-25-087885.hdr.sgml : 20250618 20250618160605 ACCESSION NUMBER: 0000950170-25-087885 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20250617 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250618 DATE AS OF CHANGE: 20250618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aura Biosciences, Inc. CENTRAL INDEX KEY: 0001501796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 320271970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40971 FILM NUMBER: 251056928 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: (617)500-8864 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 8-K 1 aura-20250617.htm 8-K 8-K false 0001501796 0001501796 2025-06-17 2025-06-17   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025     Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           80 Guest Street   Boston, Massachusetts   02135 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 617 500-8864   Not Applicable (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.00001 par value per share   AURA   The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 5.07 Submission of Matters to a Vote of Security Holders.   On June 17, 2025, Aura Biosciences, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The proposals set forth below were submitted to the stockholders at the Annual Meeting, with each such proposal described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 24, 2025. The number of shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), entitled to vote at the Annual Meeting was 50,268,758. The number of shares of Common Stock present or represented by valid proxy at the Annual

View on Read The Filing